559 related articles for article (PubMed ID: 29145973)
1. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
[TBL] [Abstract][Full Text] [Related]
2. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
[TBL] [Abstract][Full Text] [Related]
3. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1-activated kinase-1 regulates inflammation and fibrosis in the obstructed kidney.
Ma FY; Tesch GH; Ozols E; Xie M; Schneider MD; Nikolic-Paterson DJ
Am J Physiol Renal Physiol; 2011 Jun; 300(6):F1410-21. PubMed ID: 21367917
[TBL] [Abstract][Full Text] [Related]
5. TAK1 inhibition prevents the development of autoimmune diabetes in NOD mice.
Cao H; Lu J; Du J; Xia F; Wei S; Liu X; Liu T; Liu Y; Xiang M
Sci Rep; 2015 Oct; 5():14593. PubMed ID: 26459028
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal inhibition between the transforming growth factor-β-activated kinase 1 (TAK1) and apoptosis signal-regulating kinase 1 (ASK1) mitogen-activated protein kinase kinase kinases and its suppression by TAK1-binding protein 2 (TAB2), an adapter protein for TAK1.
Kim SY; Shim JH; Chun E; Lee KY
J Biol Chem; 2012 Jan; 287(5):3381-91. PubMed ID: 22167179
[TBL] [Abstract][Full Text] [Related]
7. POPX2 phosphatase regulates apoptosis through the TAK1-IKK-NF-κB pathway.
Weng T; Koh CG
Cell Death Dis; 2017 Sep; 8(9):e3051. PubMed ID: 28906490
[TBL] [Abstract][Full Text] [Related]
8. Targeting of TAK1 in inflammatory disorders and cancer.
Sakurai H
Trends Pharmacol Sci; 2012 Oct; 33(10):522-30. PubMed ID: 22795313
[TBL] [Abstract][Full Text] [Related]
9. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition.
Strippoli R; Benedicto I; Foronda M; Perez-Lozano ML; Sánchez-Perales S; López-Cabrera M; Del Pozo MÁ
J Cell Sci; 2010 Dec; 123(Pt 24):4321-31. PubMed ID: 21098640
[TBL] [Abstract][Full Text] [Related]
10. The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.
Gardner A; Fisher AJ; Richter C; Johnson GE; Moisey EJ; Brodlie M; Ward C; Krippner-Heidenreich A; Mann DA; Borthwick LA
Am J Pathol; 2012 Jun; 180(6):2293-308. PubMed ID: 22525462
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells.
Strippoli R; Benedicto I; Perez Lozano ML; Pellinen T; Sandoval P; Lopez-Cabrera M; del Pozo MA
PLoS One; 2012; 7(2):e31492. PubMed ID: 22384029
[TBL] [Abstract][Full Text] [Related]
12. Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer.
Ataie-Kachoie P; Badar S; Morris DL; Pourgholami MH
Mol Cancer Res; 2013 Oct; 11(10):1279-91. PubMed ID: 23858099
[TBL] [Abstract][Full Text] [Related]
13. TAK1 selective inhibition: state of the art and future opportunities.
Kilty I; Jones LH
Future Med Chem; 2015; 7(1):23-33. PubMed ID: 25582331
[TBL] [Abstract][Full Text] [Related]
14. Identification of TGF-β-activated kinase 1 as a possible novel target for renal cell carcinoma intervention.
Meng F; Li Y; Tian X; Fu L; Yin Y; Sui C; Ma P; Jiang Y
Biochem Biophys Res Commun; 2014 Oct; 453(1):106-11. PubMed ID: 25261726
[TBL] [Abstract][Full Text] [Related]
15. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.
Shim JH; Xiao C; Paschal AE; Bailey ST; Rao P; Hayden MS; Lee KY; Bussey C; Steckel M; Tanaka N; Yamada G; Akira S; Matsumoto K; Ghosh S
Genes Dev; 2005 Nov; 19(22):2668-81. PubMed ID: 16260493
[TBL] [Abstract][Full Text] [Related]
16. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
[TBL] [Abstract][Full Text] [Related]
17. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
18. TAK1 regulates hepatic cell survival and carcinogenesis.
Roh YS; Song J; Seki E
J Gastroenterol; 2014 Feb; 49(2):185-94. PubMed ID: 24443058
[TBL] [Abstract][Full Text] [Related]
19. TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance.
Tripathi V; Shin JH; Stuelten CH; Zhang YE
Oncogene; 2019 Apr; 38(17):3185-3200. PubMed ID: 30626936
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling.
Moon G; Kim J; Min Y; Wi SM; Shim JH; Chun E; Lee KY
Cell Signal; 2015 Dec; 27(12):2524-33. PubMed ID: 26432169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
